DDInter1405 DDInter1819
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of developing febrile neutropenia is less than 20% in many readily used chemotherapy regimens, infections pose risks of hospitalization and mortalities. Due to the relatively short circulating half-life of filgrastim, a 20 kDa PEG moiety was covalently conjugated to the N-terminus of filgrastim (at the methionine residue) to develop longer-acting pegfilgrastim.[A29,A187607] Due to a longer half-life and slower elimination rate than filgrastim
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically target CD19 antigens. Modified T cells are infused back into the patient's body. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent.
Pegfilgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mercaptopurine
Pegfilgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon alfa-2a
Pegfilgrastim {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a
Pegfilgrastim may lead to a major life threatening interaction when taken with Cladribine